Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.

Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioural disorders in children. It has been shown that as many as 85% of patients with ADHD have at least one psychiatric co-morbidity, and approximately 60% have at least two. Atomoxetine is a specific, noradrenergic reuptake inhibitor that provides an effective treatment option for patients with ADHD and co-morbid conditions. The efficacy of atomoxetine in treating ADHD appears to be unaffected by the presence of co-morbid conditions. Therapy with atomoxetine has been associated with statistically significant improvements in symptoms of oppositional defiant disorder in most, but not all, studies. Limited data suggest this agent may have potential in improving co-occurring symptoms of anxiety and may be useful in patients with co-morbid conditions such as tics or Tourette's syndrome. The tolerability profile of atomoxetine in patients with ADHD and co-morbid conditions was similar to that of patients with uncomplicated ADHD. Atomoxetine was well tolerated, with adverse events generally mild and transient; the most frequent adverse events in patients with ADHD included abdominal pain, decreased appetite, nausea and vomiting. The favourable safety and efficacy profile of atomoxetine makes it a promising treatment for patients with ADHD and associated co-morbidities.
AuthorsGrazia Dell'Agnello, Alessandro Zuddas, Gabriele Masi, Paolo Curatolo, Dante Besana, Andrea Rossi
JournalCNS drugs (CNS Drugs) Vol. 23 Issue 9 Pg. 739-53 (Sep 2009) ISSN: 1172-7047 [Print] New Zealand
PMID19689165 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Adrenergic Uptake Inhibitors
  • Propylamines
  • Atomoxetine Hydrochloride
  • Adolescent
  • Adrenergic Uptake Inhibitors (adverse effects, pharmacology, therapeutic use)
  • Atomoxetine Hydrochloride
  • Attention Deficit Disorder with Hyperactivity (complications, drug therapy, physiopathology)
  • Child
  • Clinical Trials as Topic
  • Comorbidity
  • Humans
  • Propylamines (adverse effects, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: